ESBL- and MBL-mediated resistance in acinetobacter baumannii: A global threat to burn patients;Infezioni da acinetobacter baumannii produttori di esbl e mbl nei pazienti ustionati

Infezioni in Medicina

Volumn 20, Issue 3, 2012, Pages 182-187

  Owlia, Parviz ^a,b   Azimi, Leila ^a   Gholami, Abbas ^a,c   Asghari, Babak ^a   Lari, Abdolaziz Rastegar ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHAHED UNIVERSITY   (Iran)

^c IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Acinetobacter baumannii; Burn patients; Extendedspectrum lactamase (ESBL); Metallo lactamase

Indexed keywords

AMIKACIN; AZTREONAM; CEFOTAXIME; CEFTAZIDIME; CIPROFLOXACIN; CLAVULANATE POTASSIUM PLUS TICARCILLIN; COLISTIN; EXTENDED SPECTRUM BETA LACTAMASE; GENTAMICIN; IMIPENEM; KANAMYCIN; METALLO BETA LACTAMASE; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; TICARCILLIN; TOBRAMYCIN; TRIMETHOPRIM;

ACINETOBACTER BAUMANNII; ADOLESCENT; ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATION; BURN; CHILD; CONTROLLED STUDY; FEMALE; HOSPITALIZATION; HUMAN; INFANT; IRAN; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PRESCHOOL CHILD; SCHOOL CHILD;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; BURN UNITS; BURNS; CARBAPENEMS; CEFTAZIDIME; CHILD; CHILD, PRESCHOOL; CROSS INFECTION; DRUG COMBINATIONS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HOSPITALS, UNIVERSITY; HUMANS; INFANT; IRAN; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PHENOTYPE; PREVALENCE; YOUNG ADULT;

EID: 84866930687     PISSN: 11249390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Church D., Elsayed S., Reid O., Winston B., Lindsay R. Burn wound infections. Clin. Microbiol. Rev. 19, 403- 434, 2006.
2. Sharma B.R. Infection in patients with severe burns: causes and prevention thereof. Infect. Dis. Clin. North Am. 21, 745-759, 2007.
3. Moellering R. Jr. Antibiotic resistance: lessons for the future. Clin. Infect. Dis. 27 (Suppl. 1), S135-S140; discussion S141-S142, 1998.
4. Perez F., Hujer A.M., Hujer K.M., Decker B.K., Rather P.N., Bonomo R.A. Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob. Agents Chemother. 51, 3471-3484, 2007.
5. Walsh T.R. Emerging carbapenemases: a global perspective. Int. J. Antimicrob. Agents. 36, S8-S14, 2010.
6. Ricciardi R., Ricciardi A.M., Danzi G. In vitro activity of tigecycline against multidrug-resistant Acinetobacter baumannii clinical isolates. Infezioni in Medicina 4, 236-239, 2009.
7. Azimi L., Motevallian A., Ebrahimzadeh Namvar A., Asghari B., Rastegar Lari A. Nosocomial infections in burnt patients in Motahari Hospital, Tehran, Iran. Dermatol. Res. Pract. 1-4, 2011.
8. Vila J., Pachón J. Therapeutic options for Acinetobacter baumannii infections. Expert. Opin. Pharmacother. 9, 587-599, 2008.
9. Dalla-Costa L.M., Coelho J.M., Souza H.A., et al. Outbreak of carbapenem-resistant Acinetobacter baumannii producing the OXA-23 enzyme in Curitiba, Brazil. J. Clin. Microbiol. 41, 3403-3406, 2003.
10. Peleg A.Y., Seifert H., Paterson D.L. Acinetobacter baumannii: emergence of a successful pathogen. Clin. Microbiol Rev. 21, 538-582, 2008.
11. Saderi H., Lotfalipour H., Owlia P., Salimi H. Detection of MBL producing Pseudomonas aeruginosa isolated from burn patients in Tehran, Iran. Lab Medicine 41, 17-20, 2010.
12. Yousefi S., Farajnia S., Nahaei M.R., et al. Detection of metallo-β-lactamase encoding genes among clinical isolates of Pseudomonas aeruginosa in northwest of Iran. Diagn. Microbiol Infect Dis. 68, 322-325, 2010.
13. Poirel L., Menuteau O., Agoli N., Cattoen C., Nordmann P. Outbreak of Extended-Spectrum β-Lactamase VEB-1-Producing Isolates of Acinetobacter baumannii in a French Hospital. J. Clin Microbiol. 41, 3542-3547, 2003.
14. Qader A.R., Muhamad J.A. Nosocomial infection in sulaimani burn hospital, Iraq. Ann. Burns Fire Disasters 23, 177-181, 2010.
15. Vahaboglu H., Coskunkon F., Tansel O., Ozturk R., Sahin N., Koksal I. Clinical importance of extendedspectrum β-Lactamase (PER-1-type)-producing Acinetobacter spp. and P. aeruginosa strains. J. Med. Microbiol. 50, 642-645, 2001.
16. Bellissima P., Rosalba Amato R. Incidence of extended spectrum beta-lactamase (ESBL)-producing Enterobacteria in the area of Caltagirone (Sicily). Infezioni in Medicina 2, 108-112, 2004.
17. Ramazanzadeh R., Chitsaz M., Bahmani N. Prevalence and antimicrobial susceptibility of Extended- Spectrum β-Lactamase producing bacteria in Intensive Care Units of Sanandaj General Hospitals (Kurdistan, Iran). Chemotherapy 55, 287-292, 2009.
18. Tascini C., Mantengoli E., Gemignani G., et al. In vitro synergism of ulifloxacin pluspiperacillin/ tazobactam against clinical isolates of Enterobacteriaceae producing extended-spectrum or AmpC-Type beta-lactamases. Infezioni in Medicina 4, 243-247, 2010.
19. Jazani N.H., Babazadeh H., Sohrabpour M., Zartoshti M., Ghasemi-Rad M. The prevalence of extended spectrum beta-lactamases in Acinetobacter baumannii isolates from burn wounds in Iran. The Internet Journal of Microbiology 9, 2, 2011.
20. Soltan Dallal M.M., Azarsa M., Shirazi M.H., et al. The prevalence of ESBLs and CTX-M-1 producing Escherichia coli in urine samples collected at Tabriz city Hospitals. Tehran University Medical Journal 69, 273-278, 2011.
21. Sharifi Yazdi M.K., Soltan Dallal M.M., Mirzaei Molla Agha H., et al. Molecular detection of TEM broad spectrum β-lactamase in clinical isolates of Escherichia coli. Afr. J. Biotech.10, 9454-9458, 2011.
22. Yong D., Shin J.H., Kim S., et al. High prevalence of PER-1 extended-spectrum β-lactamase producing Acinetobacter spp. in Korea. Antimicrob. Agents Chemother. 47, 1749-1751, 2003.
23. Pino C., Domínguez M.Y., González R.G., et al. Extended spectrum beta lactamases (ESBL) production in Acinetobacter baumannii strains isolated from Chilean hospitals belonging to VIII Region. Rev. Chilena Infectol. 24, 137-141, 2007.
24. Tawfiq J.A., Anani A.A. Antimicrobial susceptibility pattern of bacterial pathogens causing urinary tract infections in a Saudi Arabian hospital. Chemotherapy 55,127-131, 2009.
25. Rastegar Lari A., Bahrami Honar H., Alaghehbandan R. Pseudomonas infections in Tohid Burn Center, Iran. Burns 24, 637-641, 1998.
26. Anuradha S.De., Simit H., Kumar., Baveja M.S. Prevalence of metallo-β-lactamase producing Pseudomonas aeruginosa and Acinetobacter species in intensive care areas in a tertiary care hospital. Indian. J. Crit Care Med. 14, 217-219, 2010.
27. Peymani A., Nahaei M.R., Farajnia S., et al. High Prevalence of Metallo-β-Lactamase-Producing Acinetobacter baumannii in a Teaching Hospital in Tabri, Iran. Jpn. J. Infect. Dis. 64, 69-71, 2011.
28. Sinha M., Srinivasa H., Macaden R. Antibiotic resistance profile and extended spectrum beta-lactamase (ESBL) production in Acinetobacter species. Indian. J. Med. Res. 126, 63-67, 2007.
29. Diamante P., Camporese A. Evaluation of Vitek 2 performance for identifying extended spectrum betalactamases in Enterobacteriaceae "other than Escherichia coli, Proteus mirabilis and Klebsiella spp". Infezioni in Medicina 4, 216-226, 2006.
30. Salimi H., Yakhchali B., Owlia P., Rastegar Lari A. Molecular Epidemiology and Drug Susceptibility of Pseudomonas aeruginosa Strains Isolated from Burn Patients. Lab Medicine 41, 6-10, 2010.
31. Kaleem F., Usman J., Hassan A., Khan A. Frequency and susceptibility pattern of metallo-β-lactamase producers in a hospital in Pakistan. J. Infect. Dev. Ctries 4, 810-813, 2010.
32. Mohamed N.M., Raafat D. Phenotypic and genotypic detection of metallo-beta-lactamases in imipenem- resistant Acinetobacter baumannii isolated from a tertiary hospital in Alexandria, Egypt. Research Journal of Microbiology 6, 750-760, 2011.
33. Yong D., Choi Y.S., Roh K.H., et al. Increasing prevalence and diversity of MBLs in Pseudomonas spp., Acinetobacter spp., and Enterobacteriaceae from Korea. Antimicrob. Agents Chemother. 50, 1884-1886, 2006.
34. Rastegar Lari A., Azimi L., Rahbar M., Fallah F., Alaghehbandan R. Phenotypic detection of Klebsiella pneumoniae carbapenemase among burns patients: First report from Iran. Burns June 11, 2012.
35. Gattuso G., Tomasoni D., Palvarini L., et al. Epidemiology of ESBL-positive Enterobacteriaceae in Mantova hospital (Italy). Infezioni in Medicina 3, 164-168, 2009.
36. Joshi S.G., Litake G.M., Ghole V.S., Niphadkar K.B. Plasmid borne extended spectrum lactamase in a clinical isolate of Acinetobacter baumannii. J. Med. Microbiol. 52, 1125-1127, 2003.
37. Behera B., Mathur P., Das A., Kapil A., Sharma V. An evaluation of four different phenotypic techniques for detection of MBL producing Pseudomonas aeruginosa. Indian J. Med. Microbiol. 26, 233-237, 2008.
38. Grandesso S., Sapino B., Mazzucato S., Alessandrini R., Solinas M., Gion M. Study on in vitro susceptibility of ESBL-positive Escherichia coli isolated from urine specimens. Infezioni in Medicina 18, 162-168, 2010.
39. Noviello S., Ianniello F., Leone S., Fiore M., Esposito S. In vitro activity of tigecycline: MICs, MBCs, timekill curves andpost-antibiotic effect. J. Chemother. 20, 5, 577-80, 2008
40. Esposito S., Esposito I., Leone S. Considerations of antibiotic therapy duration in community- and hospital- acquired bacterial infections. J. Antimicrob. Chemother. 2012 Jul 24 [Epub ahead of print].
41. Bassetti M., Nicolini L., Esposito S., Righi E., Viscoli C. Current status of newer carbapenems. Curr. Med. Chem. 16, 5, 564-575, 2009.
42. Bassetti M., Righi E., Esposito S., Petrosillo N., Nicolini N. Drug treatment for multidrug resistant Acinetobacter baumannii. Future Microbiol. 3, 6, 649-660, 2008.
43. Esposito S., Leone S. Antimicrobial treatment for Intensive Care Unit (ICU) infections including the role of the infectious diseases specialist. Inter. J. Antimicrob. Agents. 29, 494-500, 2007.
44. Petrosillo N., Chinello P., Proietti MF, Cecchini L., Masala M., Franchi C., Venditti M., Esposito S., Nicastri E. Combined colistin and rifampicin therapy for carbapenem- resistant Acinetobacter baumannii infections: clinical outcomes and adverse events. Clin. Microbiol. Infect. 11, 682-684, 2005.